New shot aims to stop liver damage in rare genetic disease
NCT ID NCT03945292
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study tested a drug called fazirsiran in 40 adults with Alpha-1 antitrypsin deficiency, a genetic condition that can cause liver disease. The drug is designed to lower levels of a harmful protein (Z-AAT) in the blood. Researchers measured safety and how much the protein dropped after 16 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fazirsiran (also called TAK-999 or ARO-AAT), given as a shot under the skin
What this could lead to
If it works, this could lead to a treatment that lowers the toxic protein buildup in the liver, potentially slowing or stopping liver damage in people with Alpha-1 antitrypsin deficiency.
What could go wrong
This is an early (Phase 2) trial with only 40 participants, so results may not apply to everyone. The drug may not work as hoped, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Charleston, South Carolina, 29425, United States
-
Research Site 10
St Louis, Missouri, 63104, United States
-
Research Site 11
Sacramento, California, 95817, United States
-
Research Site 12
New York, New York, 10032, United States
-
Research Site 13
Stanford, California, 94305, United States
-
Research Site 14
La Jolla, California, 92037, United States
-
Research Site 15
San Francisco, California, 94158, United States
-
Research Site 16
Salt Lake City, Utah, 84132, United States
-
Research Site 17
Los Angeles, California, 90095, United States
-
Research Site 19
Houston, Texas, 77030, United States
-
Research Site 2
Gainesville, Florida, 32610, United States
-
Research Site 20
Barcelona, 08035, Spain
-
Research Site 22
Pavia, 27100, Italy
-
Research Site 23
Leiden, 2333 ZA, Netherlands
-
Research Site 24
Funchal, 9004-514, Portugal
-
Research Site 27
Aachen, 52074, Germany
-
Research Site 3
Iowa City, Iowa, 52242, United States
-
Research Site 4
Nashville, Tennessee, 37232, United States
-
Research Site 5
Birmingham, Alabama, 35233, United States
-
Research Site 7
Indianapolis, Indiana, 46202, United States
-
Research Site 9
Phoenix, Arizona, 85054, United States